



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 28, 2014 6:00 – 8:15 p.m.

***** Please note new times *****

- 1. Executive Session** **6:00 - 6:15**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:25**
 - Updates

- 4. Medical Director Update** **6:25 - 6:30**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:30 – 6:40**
 - New Cholesterol Treatment Guidelines

- 6. RetroDUR/DUR** **6:40 – 7:20**
 - Oxycodone IR/Hydromorphone IR Retrospective Drug Utilization Review

- 7. Clinical Update: Drug Reviews** **7:20 – 7:50**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Oxytrol[®] (oxybutynin transdermal system) OTC
 - Vecamyl[®] (mecamylamine) Oral Tablet

 - Full New Drug Reviews**
 - Breo Ellipta[®] (fluticasone furoate and vilanterol inhalation powder) Inhaler
 - Olysio[®] (simeprevir) Oral Capsule
 - Sovaldi[®] (sofosbuvir) Oral Tablet

- 8. Clinical Update: New/Updated Clinical Guidelines** **7:50 – 8:00**
(Public comment prior to Board action)
 - JNC 8 Hypertension Guidelines

- 9. Therapeutic Drug Classes – Periodic Review** **8:00 – 8:00**
(Public comment prior to Board action)
 - None

- 10. New Managed Therapeutic Drug Classes** **8:00– 8:00**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:00 – 8:10**
(Public comment prior to Board action)
- Anti-Hyperkinesia and Anti-Narcolepsy/Cataplexy
 - Ilaris[®] (canakinumab) Injection in SJIA (new FDA approved diagnosis)
 - Miscellaneous: Soliris[®] (eculizumab)
- 12. General Announcements** **8:10– 8:15**
Selected FDA Safety Alerts
- Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement - Recommendation to Discontinue Prescribing and Dispensing
 - Onfi[®] (clobazam): Drug Safety Communication - Risk of Serious Skin Reactions
- 13. Adjourn** **8:15**